表紙
市場調査レポート

糖尿病性神経障害治療薬:パイプライン分析および2017年までの市場予測

Diabetic Neuropathy Therapeutics - Pipeline Assessment and Market Forecasts to 2017

発行 GlobalData 商品コード 172351
出版日 ページ情報 英文 86 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
糖尿病性神経障害治療薬:パイプライン分析および2017年までの市場予測 Diabetic Neuropathy Therapeutics - Pipeline Assessment and Market Forecasts to 2017
出版日: 2011年03月01日 ページ情報: 英文 86 Pages
概要

当レポートでは、糖尿病性神経障害治療薬市場におけるパイプライン分析および2017年までの市場予測を行っており、競合、パイプラインなどを評価分析し、将来の市場競争動向、企業プロファイルを盛り込んで、概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

  • 疾病の概要
  • 病因と病態生理学
  • 疫学
  • 症状
  • 診断
  • 処置と管理パターン
  • ガイダンス

第3章 糖尿病性神経障害治療薬市場の特徴

  • 世界市場の規模(2005−2010年)
  • 世界市場の予測(2010−2017年)
  • 米国市場の規模(2005−2010年)
  • 米国市場の予測(2010−2017年)
  • フランス市場の規模(2005−2010年)
  • フランス市場の予測(2010−2017年)
  • ドイツ市場の規模(2005−2010年)
  • ドイツ市場の予測(2010−2017年)
  • イタリア市場の規模(2005−2010年)
  • イタリア市場の予測(2010−2017年)
  • スペイン市場の規模(2005−2010年)
  • スペイン市場の予測(2010−2017年)
  • 英国市場の規模(2005−2010年)
  • 英国市場の予測(2010−2017年)
  • 日本市場の規模(2005−2010年)
  • 日本市場の予測(2010−2017年)
  • 市場促進および阻害要因
  • 機会およびアンメットニーズ
  • 要点

第4章 競合のアセスメント

  • 概要
  • 戦略的競合評価
  • 主な市販製品のプロファイル
  • 要点

第5章 パイプラインのアセスメント

  • 概要
  • 戦略的パイプライン評価
  • 開発段階別のパイプライン
  • 作用機序別の臨床パイプライン
  • 技術動向分析の枠組み
  • 有望な臨床開発中の治療薬
  • 有望な臨床開発中治療薬の分子プロファイル
  • 要点

第6章 臨床試験の状況

  • 国別の臨床試験
  • 開発段階別の臨床試験
  • 試験段階別の臨床試験
  • 有望なスポンサー
  • 臨床試験中の上位企業

第7章 戦略的競合評価

  • 将来の市場に影響を与える主な出来事
  • 将来の市場競争についての示唆

第8章 将来の企業

  • イントロダクション
  • 企業プロファイル

第9章 認可と提携取引

第10章 付録

図表

目次
Product Code: GDHC205PRT

Summary

GlobalData, the industry analysis specialist, has released its new report, “Diabetic Neuropathy Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global diabetic neuropathy market. The report identifies the key trends shaping and driving the global diabetic neuropathy market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global diabetic neuropathy sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData’s analysis suggests that the global DN market was worth $1.41 billion in 2010. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 8.5% for the next seven years, to reach $2.49 billion by 2017. This is primarily attributed to the increase in the prevalence of the disease and the strong pipeline with new first-in-class therapies.

Scope

The report provides information on the key drivers and challenges of the diabetic neuropathy market. Its scope includes -

• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) diabetic neuropathy market revenues data from 2005 to 2010, forecast for seven years to 2017.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as NMDA receptor agonist, nerve growth factor enhancer, gamma-aminobutyric acid agonist, serotonin and norepinephrine reuptake inhibitor and alpha2 receptor antagonist.
• Analysis of the current and future competition in the seven key countries diabetic neuropathy market. Key market players covered are AstraZeneca, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), Takeda Pharmaceuticals, Mitsubishi Chemical Holdings Corporation, Avanir Pharmaceuticals, Arcion Therapeutics, Inc., Dong-A Pharmaceutical Co., Ltd., EpiCept.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the diabetic neuropathy therapeutics market.
• Analysis of key recent licensing and partnership agreements in diabetic neuropathy market

Reasons To Buy

The report will enhance your decision making capability. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global diabetic neuropathy market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global diabetic neuropathy market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global diabetic neuropathy market landscape? – Identify, understand and capitalize.

Companies Mentioned

AstraZeneca PLC

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (Subsidiary of

Johnson & Johnson)

Takeda Pharmaceutical Company Limited

Mitsubishi Chemical Holdings Corporation

Avanir Pharmaceuticals

Arcion Therapeutics

Dong-A Pharmaceutical Co., Ltd.

EpiCept Corporation

MediciNova, Inc.

Quigley Pharma, Inc.

Sangamo BioSciences, Inc.

Table of Contents

1. Table of contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Diabetic Neuropathy Therapeutics -- Executive Summary

  • 2.1. The Diabetic Neuropathy (DN) Therapeutics Market is forecast to Show Steady Growth Until 2017
  • 2.2. Current Diabetic Neuropathy Market is Weak due to the Limited Availability of Treatment Options Targeting Disease Progression
  • 2.3. The Diabetic Neuropathy Therapeutics Market has High Unmet Need
  • 2.4. Strong Pipeline with Several First-in-Class Molecules
  • 2.5. Future Implications for the Diabetic Neuropathy Therapeutics Market

3. Diabetic Neuropathy Therapeutics - Introduction

  • 3.1. Overview
  • 3.2. Etiology and Pathophysiology
  • 3.3. Epidemiology
  • 3.4. Symptoms
  • 3.5. Diagnosis
  • 3.6. Treatment and Management Pattern
  • 3.7. GlobalData Report Guidance

4. Diabetic Neuropathy Therapeutics - Market Characterization

  • 4.1. Diabetic Neuropathy Therapeutics Market Size (2005-2010) - Global
  • 4.2. Diabetic Neuropathy Therapeutics Market Forecast (2010-2017) - Global
  • 4.3. Diabetic Neuropathy Therapeutics Market Size (2005-2010): The US
  • 4.4. Diabetic Neuropathy Therapeutics Market Forecast (2010-2017): The US
  • 4.5. Diabetic Neuropathy Therapeutics Market (2005-2010): France
  • 4.6. Diabetic Neuropathy Therapeutics Market Forecast (2010-2017): France
  • 4.7. Diabetic Neuropathy Therapeutics Market (2005-2010): Germany
  • 4.8. Diabetic Neuropathy Therapeutics Market Forecast (2010-2017): Germany
  • 4.9. Diabetic Neuropathy Therapeutics Market (2005-2010): Italy
  • 4.10. Diabetic Neuropathy Therapeutics Market Forecast (2010-2017): Italy
  • 4.11. Diabetic Neuropathy Therapeutics Market (2005-2010): Spain
  • 4.12. Diabetic Neuropathy Therapeutics Market Forecast (2010-2017): Spain
  • 4.13. Diabetic Neuropathy Therapeutics Market (2005-2010): The UK
  • 4.14. Diabetic Neuropathy Therapeutics Market Forecast (2010-2017): The UK
  • 4.15. Diabetic Neuropathy Therapeutics Market (2005-2010): Japan
  • 4.16. Diabetic Neuropathy Therapeutics Market Forecast (2010-2017): Japan
  • 4.17. Drivers and Barriers for the Diabetic Neuropathy Therapeutics Market
  • 4.17.1. Drivers for the Diabetic Neuropathy Therapeutics Market
  • 4.17.2. Barriers for the Diabetic Neuropathy Therapeutics Market
  • 4.18. Opportunity and Unmet Need Analysis
  • 4.19. Key Takeaway

5. Diabetic Neuropathy Therapeutic - Competitive Assessment

  • 5.1. Overview
    • 5.1.1. Strategic Competitor Assessment
  • 5.2. Product Profile for the Major Marketed Products in the Diabetic Neuropathy Therapeutics Market
    • 5.2.1. Cymbalta (Duloxetine Hydrochloride)
    • 5.2.2. Lyrica (Pregablin)
  • 5.3. Key Takeaway

6. Diabetic Neuropathy Therapeutics - Pipeline Assessment

  • 6.1. Overview
  • 6.2. Strategic Pipeline Assessment
  • 6.3. Diabetic Neuropathy Therapeutics Pipeline -- Pipeline by Phases of Development
    • 6.3.1. Diabetic Neuropathy Therapeutics -- Phase III Pipeline
    • 6.3.2. Diabetic Neuropathy Therapeutics -- Phase II Pipeline
    • 6.3.3. Diabetic Neuropathy Therapeutics-- Phase I Pipeline
    • 6.3.4. Diabetic Neuropathy Therapeutics -- Preclinical Pipeline
    • 6.3.5. Diabetic Neuropathy Therapeutics -- Discovery Pipeline
  • 6.4. Diabetic Neuropathy Therapeutics Market -- Clinical Pipeline by Mechanism of Action
  • 6.5. Technology Trends Analytical Framework
  • 6.6. Diabetic Neuropathy Therapeutics -- Promising Drugs under Development
  • 6.7. Molecule Profile for Promising Drugs Under Development
    • 6.7.1. AS-3201 (ranirestat)
    • 6.7.2. AVP-923 (Zenvia)
    • 6.7.3. Nucynta ER (tapentadol)
  • 6.8. Key Takeaway

7. Diabetic Neuroapthy Therapeutics - Clinical Trials Mapping

  • 7.1. Clinical Trials by Region/Country (US, EU5 & Japan)
  • 7.2. Clinical Trials by Phase
  • 7.3. Clinical Trials by Trial Status
  • 7.4. Prominent Sponsors
  • 7.5. Key Companies Participating in Therapeutics Clinical Trials

8. Diabetic Neuropathy Therapeutics - Stategic Assessment

  • 8.1. Key Events Impacting on the Future Market
  • 8.2. Diabetic Neuropathy Therapeutics: Implications for Future Market Competition

9. Diabetic Neuropathy Therapeutics - Future Players

  • 9.1. Introduction
  • 9.2. Company Profiles
    • 9.2.1. AstraZeneca PLC
    • 9.2.2. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (Subsidiary of Johnson & Johnson)
    • 9.2.3. Takeda Pharmaceutical Company Limited
    • 9.2.4. Mitsubishi Chemical Holdings Corporation
    • 9.2.5. Avanir Pharmaceuticals
    • 9.2.6. Arcion Therapeutics
    • 9.2.7. Dong-A Pharmaceutical Co., Ltd.
    • 9.2.8. EpiCept Corporation
    • 9.2.9. MediciNova, Inc.
    • 9.2.10. Quigley Pharma, Inc.
    • 9.2.11. Sangamo BioSciences, Inc.
    • 9.2.12. Other Companies in the Diabetic Neuropathy Therapeutics Market

10. Diabetic Neuropathy Therapeutics - Licensing and Partnership Deals

11. Diabetic Neuropathy Therapeutics - Appendix

  • 11.1. Market Definitions
  • 11.2. Abbreviations
  • 11.3. Methodology
    • 11.3.1. Coverage
    • 11.3.2. Secondary Research
    • 11.3.3. Forecasting
    • 11.3.4. Primary Research
    • 11.3.5. Expert Panels Validation
  • 11.4. Contact Us
  • 11.5. Disclaimer
  • 11.6. Bibliography

List of Tables

  • Table 1: Diabetic Neuropathy-Primary Classification
  • Table 2: Neurological Distribution of Diabetic Neuropathy
  • Table 3: Diabetic Neuropathy Therapeutics Market, Global, Revenue($bn), 2005-2010
  • Table 4: Diabetic Neuropathy Therapeutics Market, Global, Forecast($bn), 2010-2017
  • Table 5: Diabetic Neuropathy Therapeutics Market, The US, Revenue($m), 2005-2010
  • Table 6: Diabetic Neuropathy Therapeutics Market, The US, Forecast($m), 2010-2017
  • Table 7: Diabetic Neuropathy Therapeutics Market, France, Revenue($m), 2005-2010
  • Table 8: Diabetic Neuropathy Therapeutics Market, France, Forecast($m), 2010-2017
  • Table 9: Diabetic Neuropathy Therapeutics Market, Germany, Revenue($m), 2005-2010
  • Table 10: Diabetic Neuropathy Therapeutics Market, Germany, Forecast ($m), 2010-2017
  • Table 11: Diabetic Neuropathy Therapeutics Market, Italy, Revenue ($m), 2005-2010
  • Table 12: Diabetic Neuropathy Therapeutics Market, Italy, Forecast ($m), 2010-2017
  • Table 13: Diabetic Neuropathy Therapeutics Market, Spain, Revenue ($m), 2005-2010
  • Table 14: Diabetic Neuropathy Therapeutics Market, Spain, Forecast ($m), 2010-2017
  • Table 15: Diabetic Neuropathy Therapeutics Market, The UK, Revenue ($m), 2005-2010
  • Table 16: Diabetic Neuropathy Therapeutics Market, The UK, Forecast ($m), 2010-2017
  • Table 17: Diabetic Neuropathy Therapeutics Market, Japan, Revenue ($m), 2005-2010
  • Table 18: Diabetic Neuropathy Therapeutics Market, Japan, Forecast ($m), 2010-2017
  • Table 19: Clinical Trials of Cymbalta
  • Table 20: Clinical Trials of Lyrica
  • Table 21: Major Marketed Products in the DN Therapeutics Market, 2011
  • Table 22: DN Therapeutics Market -- Phase III Pipeline, 2011
  • Table 23: DN Therapeutics Market -- Phase II Pipeline, 2011
  • Table 24: DN Therapeutics Market -- Phase I Pipeline, 2011
  • Table 25: DN Therapeutics Market -- Preclinical Pipeline, 2011
  • Table 26: DN Therapeutics Market -- Discovery Pipeline, 2011
  • Table 27: DN Therapeutics --Most Promising Drugs Under Development, 2011
  • Table 28: Diabetic Neuropathy Therapeutics Market, Clinical Trials by Region, 2011
  • Table 29: Diabetics Neuropathy Therapeutics Market, Global, Clinical Trials by Phase of Development, 2011
  • Table 30: Diabetics Neuropathy Therapeutics Market, Global, Clinical Trials by Trial Status, 2011
  • Table 31: Diabetic Neuropathy Therapeutics Market, Global, Clinical Trials by Overall Sponsors, 2011
  • Table 32: Diabetic Neuropathy Therapeutics Market, Global, Clinical Trials by Prominent Sponsors, 2011
  • Table 33: Diabetic Neuropathy Therapeutics Market, Global, Clinical Trials by Lead Sponsors, 2011
  • Table 34: AstraZeneca PLC - CNS Pipeline Portfolio, 2011
  • Table 35: AstraZeneca PLC.-Deals, 2011
  • Table 36: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.-CNS Pipeline Portfolio, 2011
  • Table 37: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.-Deals, 2011
  • Table 38: Takeda Pharmaceutical Company Limited -- CNS pipeline products, 2011
  • Table 39: Takeda Pharmaceutical Company Limited -- Deals, 2011
  • Table 40: Mitsubishi Chemical Holdings Corporation -- CNS Pipeline Portfolio, 2011
  • Table 41: Avanir Pharmaceuticals -- CNS pipeline products, 2011
  • Table 42: Avanir Pharmaceuticals-Deals, 2011
  • Table 43: Dong-A Pharmaceuticals -- CNS pipeline products, 2011
  • Table 44: Dong-A Pharmaceuticals -- Deals, 2011
  • Table 45: EpiCept Corporation -- CNS pipeline products, 2011
  • Table 46: EpiCept Corporation -- Deals, 2011
  • Table 47: Medicinova Inc. -- CNS pipeline products, 2011
  • Table 48: Medicinova Inc. -- Deals, 2011
  • Table 49: Sangamo BioSciences, Inc.-CNS pipeline Portfolio,2011
  • Table 50: Sangamo BioSciences, Inc.-Deals,2011
  • Table 51: Other Companies in the Pipeline, 2011
  • Table 52: Licensing and Partnership Deals

List of Figures

  • Figure 1: Types of Neuropathic Pain
  • Figure 2: Pathophysiology of Diabetic Neuropathy
  • Figure 3: Progression of Diabetic Neuropathy
  • Figure 4: Signs and symptoms of Diabetic Peripheral Neuropathy (DPN)
  • Figure 5: Stages of Disease Severity and Treatment of Diabetic Peripheral Neuropathy (Numbness and Pain)
  • Figure 6: Diabetic Neuropathy Therapeutics Market, Global, Revenue($bn), 2005-2010
  • Figure 7: Diabetic Neuropathy Therapeutics Market, Global, Forecast($bn), 2010-2017
  • Figure 8: Diabetic Neuropathy Therapeutics Market, The US, Revenue($m), 2005-2010
  • Figure 9: Diabetic Neuropathy Therapeutics Market, The US, Forecast($m), 2010-2017
  • Figure 10: Diabetic Neuropathy Therapeutics Market, France, Revenue($m), 2005-2010
  • Figure 11: Diabetic Neuropathy Therapeutics Market, France, Forecast($m), 2010-2017
  • Figure 12: Diabetic Neuropathy Therapeutics Market, Germany, Revenue($m), 2005-2010
  • Figure 13: Diabetic Neuropathy Therapeutics Market, Germany, Forecast ($m), 2010-2017
  • Figure 14: Diabetic Neuropathy Therapeutics Market, Italy, Revenue ($m), 2005-2010
  • Figure 15: Diabetic Neuropathy Therapeutics Market, Italy, Forecast ($m), 2010-2017
  • Figure 16: Diabetic Neuropathy Therapeutics Market, Spain, Revenue ($m), 2005-2010
  • Figure 17: Diabetic Neuropathy Therapeutics Market, Spain, Forecast ($m), 2010-2017
  • Figure 18: Diabetic Neuropathy Therapeutics Market, The UK, Revenue ($m), 2005-2010
  • Figure 19: Diabetic Neuropathy Therapeutics Market, The UK, Forecast ($m), 2010-2017
  • Figure 20: Diabetic Neuropathy Therapeutics Market, Japan, Revenue ($m), 2005-2010
  • Figure 21: Diabetic Neuropathy Therapeutics Market, Japan, Forecast ($m), 2010-2017
  • Figure 22: Opportunity and Unmet Need in the Diabetic Neuropathy Therapeutics Market, 2010
  • Figure 23: Strategic Competitor Assessment of the Major Marketed Products for Diabetic Neuropathy, 2011
  • Figure 24: DN Therapeutics Pipeline by Phase of Development, 2011
  • Figure 25: DN Therapeutics Market -- Pipeline by Mechanism of Action, 2011
  • Figure 26: Technology Trends Analytic Framework of the DN Therapeutics Pipeline, 2011
  • Figure 27: Technology Trends Analytic Framework of the DN Therapeutics Pipeline, 2011
  • Figure 28: Diabetic Neuropathy Therapeutics Market-Clinical Trials by Region, 2011
  • Figure 29: Diabetic Neuropathy Therapeutics Market, Global, Clinical Trials by Phase of Development, 2011
  • Figure 30: Diabetic Neuropathy Therapeutics Market, Global, Clinical Trials by Trial Status, 2011
  • Figure 31: Diabetic Neuropathy Therapeutics Market, Global, Clinical Trials by Overall Sponsors, 2011
  • Figure 32: Diabetic Neuropathy Therapeutics Market, Global, Clinical Trials by prominent Sponsors, 2011
  • Figure 33: Diabetic Neuropathy Therapeutics Market, Global, Clinical Trials by Top Companies, 2011
  • Figure 34: DN Therapeutics Market, Drivers and Barriers, 2011
  • Figure 35: Implications for Future Market Competition in the DN Therapeutics Market, 2011
  • Figure 36: DN Therapeutics Market -- Pipeline by Company, 2011
  • Figure 37: GlobalData Market Forecasting Model
Back to Top